Match!

Is technology integration the solution to biotechnology's low research and development productivity?

Published on May 1, 2006in Technovation5.25
· DOI :10.1016/j.technovation.2005.06.001
Arsia Amir-Aslani2
Estimated H-index: 2
(University of Paris),
Syoum Negassi4
Estimated H-index: 4
(University of Paris)
Abstract
Abstract The demand for innovative and cost-effective products has had considerable impact on the Research and Development (R&D) portfolio of pharmaceutical companies. With the advent of the new enabling technologies, the biotechnology revolution has created a need for a new and more appropriate paradigm for drug development. The progress in the biological understanding of disease processes and related technological developments have been a major step forward for drug discovery. However, the great majority of the biotechnology companies are confronted with the same issues as major pharmaceutical companies in terms of R&D productivity. This article intends to unfold the challenges faced by biotechnology companies involved in drug discovery by managing the complexity, uncertainty and urgency of technology integration through organic, acquisition and partnering strategies have become priorities for biotechnology companies in helping them achieving more efficiency in their pharmaceutical R&D efforts. Such strategies help biotechnology companies apply their technologies across a broad range of applications within the drug discovery value chain to maximize opportunities for product development. Competitive advantage in the marketplace ultimately derives from providing better speed, cost, quality and direction.
  • References (21)
  • Citations (41)
📖 Papers frequently viewed together
22k Citations
3,045 Citations
1,271 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References21
Newest
#1Michael Dickson (USC: University of South Carolina)H-Index: 13
#2Jean Paul Gagnon (Aventis Pharma)H-Index: 2
The development of a new drug requires a major investment of capital, human resources and technological expertise. It also requires strict compliance with regulations on testing and manufacturing standards before a new compound can be used in the general population. All these requirements contribute to the cost increases for new chemical entity (NCE) R&D. The central question raised by this trend is: who in the future will pay for new pharmaceutical R&D? With this question in mind, this article ...
267 CitationsSource
#1David Brown (University of Hertfordshire)H-Index: 5
Advances over the past decade in drug discovery technologies have not yet led to an increase in productivity. We analyzed the reasons that have led to this juncture and identify the selection of the right target and the right lead as crucial. New approaches are required to take full advantage of the genomics revolution. For targets, methods are becoming available for high-throughput proteome analysis and pathway characterization that synergize with studies of disease association and differential...
145 CitationsSource
4 CitationsSource
9 CitationsSource
#1Steffie Woolhandler (Harvard University)H-Index: 50
#2Terry Campbell (Harvard University)H-Index: 3
Last. David U. Himmelstein (Harvard University)H-Index: 51
view all 3 authors...
background A decade ago, the administrative costs of health care in the United States greatly exceeded those in Canada. We investigated whether the ascendancy of computerization, managed care, and the adoption of more businesslike approaches to health care have decreased administrative costs. methods For the United States and Canada, we calculated the administrative costs of health insurers, employers’ health benefit programs, hospitals, practitioners’ offices, nursing homes, and home care agenc...
445 CitationsSource
#1Gary Walsh (UL: University of Limerick)H-Index: 23
130 CitationsSource
#1Denis Noble (University of Oxford)H-Index: 68
The successful identification of drug targets requires an understanding of the high-level functional interactions between the key components of cells, organs and systems, and how these interactions change in disease states. This information does not reside in the genome, or in the individual proteins that genes code for, it is to be found at a higher level. Genomics will succeed in revolutionising pharmaceutical research and development only if these interactions are also understood by determini...
12 CitationsSource
#1Mark G EdwardsH-Index: 2
#2Fiona Murray (MIT: Massachusetts Institute of Technology)H-Index: 24
Last. Robert YuH-Index: 2
view all 3 authors...
An analysis of deal structures in biotechnology from the past 25 years reveals that universities often neglect important economic aspects in their licensing agreements.
53 CitationsSource
Abstract The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled. However, the influence of modern biology on drug discovery remains viable. The promise of genomics and biology should be put in context with the two central problems of drug discovery: the search for disease-related targets, and the study of drug–protein interactions and protein–protein interactions. The first tier of the biotechnology industry has now become the most prod...
136 CitationsSource
3 CitationsSource
Cited By41
Newest
OverviewSeveral approaches to developing new technologies are available to companies, but few studies explore how the development process can reveal hidden opportunities in existing technologies. T...
1 CitationsSource
#1Tianjiao Xia (Lboro: Loughborough University)H-Index: 4
#2Dimo DimovH-Index: 23
Engaging in exploration and exploitation is essential to business survival and performance. While firms manage exploration and exploitation alliances for the long-term, how prepared are they for sudden shocks in the short-term? We address this question in the context of a unique and opportune natural experiment associated with the 2008 financial crisis. Our analysis of 155 new biopharmaceutical ventures over a seven-year period suggests that exploration alliances – with a long-term orientation –...
1 CitationsSource
#1John Kopano Mashala (TUT: Tshwane University of Technology)
#2David Kruger (UNISA: University of South Africa)H-Index: 3
Last. L. Steynberg (TUT: Tshwane University of Technology)H-Index: 3
view all 4 authors...
This research article profiles cotton technology in the Makhathini region, focusing on the extent to which it is available to support farmers Although Makhathini Farmers have produced cotton for more than 10 years at a subsistence level, and despite using the related technology extensively, the farmers’ mission remains to produce cotton commercial. The technology mentioned in the study is available worldwide, as well as locally. The technology accessed is readily available to the local farmers. ...
Source
The paper develops an integrated technology-push and market-pull framework, a value chain model for crossing the valley of death (VOD—the gap between laboratory and market) for emerging technologies based on primary and secondary data analyses, and a survey conducted on European research and development projects. The study uses a case of micro- and nano-manufacturing technology (MNT), and confirms the existence of the VOD through the survey data analysis. A mixed-methods approach was adopted tha...
2 CitationsSource
#1Kenneth Fernald (VU: VU University Amsterdam)H-Index: 4
#2H. P. G. Pennings (EUR: Erasmus University Rotterdam)H-Index: 1
Last. Eric Claassen (VU: VU University Amsterdam)H-Index: 36
view all 5 authors...
In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innovation activities of Big Pharma firms. The study indicates a rising interest of Big Pharma in acquisitions of and alliances with biotechnology companies. Unfortunately, this increased interest is not reflected in the number of new drugs generated by Big Pharma. We find that acquisitions of biotech com...
3 CitationsSource
#1Dandan LiuH-Index: 4
#2Xiaoling PuH-Index: 1
Last. Mary E. Schramm (Quinnipiac University)H-Index: 2
view all 3 authors...
Traditionally, firms in the pharmaceutical industry have depended on their internal research and development (R&D) capabilities to maintain a productive new product pipeline. During the past two decades, however, the industry's pipeline productivity has decreased compromising the industry's ability to meet shareholder expectations. As a strategy to invigorate pipeline productivity, and impact financial performance, pharmaceutical firms have increased utilization of strategic technical alliances....
2 CitationsSource
#1Andrea Signori (University of Milan)H-Index: 9
This study addresses the signaling power of corporate innovation indicators in the IPO market. Innovation measures can convey considerably different signals to public investors, depending on whether they quantify the firm’s commitment in innovative inputs, as in the case of R&D investments, or achieved outputs, as in the case of patents. This study aims at disentangling such effects. Using a sample of 382 high-tech entrepreneurial firms going public in Europe during 1998–2003, this paper studies...
Source
#1Kenneth FernaldH-Index: 1
markdownabstractAbstract Improving medicine and health is the ultimate purpose of biotechnological innovation, where basic science is used to develop new innovative diagnostics and therapeutics to significantly improve the lives of patients worldwide. Concurrently, for three stakeholder groups, the primary goal is to generate profitable business from biotechnological innovation. These stakeholders are ‘entrepreneurial’ biotech companies, venture capitalists and established pharmaceutical firms. ...
4 Citations
#1Rahul RekhiH-Index: 2
#2David T. RyanH-Index: 2
Last. Amina A. QutubH-Index: 19
view all 5 authors...
Source
#1Joseph FeulefackH-Index: 1
#2Consolato Sergi (U of A: University of Alberta)H-Index: 25
A systematic literature review on pharmaceutical companies may be a tool for guiding some procedures of RD such as reliability of companies on “sourcing-in” R&D facilities and “think-tank” events. Regardless of the study and of the country, cash flow and profitability always positively influenced R&D expenditure, while sales and firm size did not. We consider that handling R&D determinants should require caution. It seems critical that implementation of R&D systems is directly related with produ...
1 CitationsSource